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Sphingosine kinase 1 participates in the activation,
proliferation and survival of chronic lymphocytic
leukemia cells
Sphingosine kinases (SKs) have received the most
attention as important enzymes in cancer biology. They
participate in the regulation of bioactive sphingolipid
metabolism by producing sphingosine-1 phosphate (S1P)
which mediates several biological functions, including
cell growth, differentiation, cell survival, migration, and
angiogenesis among other tasks.1 S1P generation depends
on the conversion of sphingosine to S1P, in a reaction cat-
alyzed by two isoforms of SKs, SK1 and SK2, and its lev-
els are tightly controlled via a rapid degradation by intra-
cellular S1P lyases (S1PL) or dephosphorylated by S1P
phosphatases.1 Once produced, S1P may function as an
intracellular second messenger and/or can be exported
outside the cells, where it binds to specific S1P receptors
(S1PRs) and initiates downstream signaling pathways, in
a paracrine or autocrine manner, in a process known as
“inside-out” signaling.1 
Chronic lymphocytic leukemia (CLL) is a lymphoprolif-
erative disorder characterized by the accumulation of
clonal B lymphocytes in peripheral blood and lymphoid
tissues. Given that several studies have implicated the
SKs/S1P/S1PL pathway as an essential regulator of cell
proliferation and survival in cancer cells,2-4 we evaluated
the role of SKs and S1PL in leukemic cells from CLL
patients. To this aim we first measured the basal expres-
sion of SKs messenger ribonucleic acids (mRNAs) and
S1PL mRNA by  quantitative real-time polymerase chain
reaction (qRT-PCR) on purified B cells from CLL patients
and age-matched healthy donors. We found that CLL
cells expressed heterogeneous levels of SK1, SK2 and
S1PLmRNA, while only SK1mRNA was statistically sig-
nificantly higher compared to healthy donors (Figure 1A).
As we observed at mRNA level, when SK1 was evaluated
by western blot we found a higher expression of the pro-
tein in B cells from CLL samples compared to healthy
donors (Figure 1B and Online Supplementary Figure S1A).
In addition, within CLL patients, there was a positive cor-
relation between SK1 mRNA and protein expression
(Online Supplementary Figure S1B). We also observed that
the ratio between SK1 and S1PLwas increased for B cells
from CLL patients compared to B cells from healthy
donors (Figure 1C), while no statistically significant dif-
ferences were found for SK2/S1PL ratios (Online
Supplementary Figure S1C). Remarkably, CLL patients
haematologica 2017; 102:e257
LETTERS TO THE EDITOR
Table 1. Association between SK1/S1PL ratios and different clinical and biological features of CLL patients.
variables SK1/S1PL ratios
Low High
n n n P*
Sex 30 16 14 ns
female 4 3
male 12 11
Binet 30 16 14 0.0092
A 10 2
BC 6 12
CD38 expression 30 16 14 0.0121
CD38– 11 3
CD38+ 5 11
CD49d expression 26 14 12 0.0074
CD49d– 13 5
CD49d+ 1 7
b2-microglobulin 25 14 11 ns
< 3.5  g/ml 6 5
≥ 3.5  g/ml 8 6
LDH 29 15 14 ns
< 350 U/l 7 6
≥ 350 U/l 8 8
HGB 30 16 14 ns
≤ 10 g/dl 2 8
> 10 g/dl 14 8
Platelets 30 16 14 ns
≤ 100 x 103/ul 2 3
> 100 x 103/ul 14 11
Disease progression 30 16 14 0.0355
Indolent 13 6
Progressor 3 8
IGVH mutational status 27 14 13 0.0412
Unmutated 3 8
Mutated 11 5
*Statistical significance was determined by using Fisher´s test. LDH: lactate dehydrogenase; HGB: hemoglobin; n: number of patients in each group; NS: not significant;
IGVH:  immunoglobulin variable region heavy chain. 
with higher SK1/S1PL ratios preferentially belonged to
Binet B or C clinical stages, were unmutated, CD38+,
CD49d+ and showed a progressive disease (Table 1 and
Online Supplementary Table S1), suggesting that SK1/S1PL
molecules might participate in the clinical outcome of the
patients, favoring the progression of the disease. 
Malignant B cells from CLL patients mainly receive
advantageous signals in lymphoid tissues, where the sup-
portive microenvironment and B cell receptor (BCR) sig-
naling promote their activation and proliferation, modu-
late cell adhesion and migration and protect CLL cells
from spontaneous and drug-induced apoptosis.5We have
previously reported that CLL cells activated by signals
from the supportive microenvironment transiently impair
the expression of S1PR1,6 in a process that may extend
the residency of the leukemic clone within the survival
niches of lymphoid tissues. In the study herein we want-
ed to determine whether the activation of CLL cells has
any influence on SK1/S1PL ratios. To this aim, purified B
cells from CLL patients were cultured in the presence of
immobilized Fab´2 anti-human immunoglobulin M
(anti-IgM) and CD40L, CpG or HS5 cell line as a feeder
layer and, as expected, after 24 hours of culture, the stim-
uli induced the upregulation of the activation marker
CD69 on CLL cells (data not shown). Interestingly, we
found that CLL activation enhanced SK1/S1PL ratios in
all of the patients evaluated (Figure 1D), independently of
their clinical stage or the prognosis group (data not shown).
Ibrutinib, by impairing leukemic cell activation (data not
shown) was able to strongly reduce the upregulation of
SK1/S1PL ratios induced by the stimulus (Online
Supplementary Figure S2).  Moreover, in order to evaluate
the expression of SK1/S1PL ratios within in vivo activated
CLL cell subpopulations, we took advantage of the fact
that we had previously obtained mRNA samples of in vivo
activated CLL cells subpopulations and non-activated
counterparts of the same patient.6 When  SK1, SK2 and
S1PL mRNA levels were evaluated in the proliferative
fraction of circulating CLL cells (PF, IgG+ cells), described
by Palacios et al.,7 and the quiescent fraction from the
same patient (IgM+IgG– cells, QF), we found higher
SK1/S1PL ratios in the PF of  the three CLL patients eval-
uated (Figure 1E). Additionally, bone marrow leukemic
cells expressing high levels of CD38, which defines a sub-
population of activated lymphocytes, showed higher
SK1/S1PL ratios compared to their CD38 low or negative
counterparts (n=3) (Figure 1F), indicating that in vivo acti-
vated CLL cells expressed higher ratios of SK1/S1PL com-
pared with the rest of the leukemic clone.
Subsequently, to test whether the inhibition of SKs
could modify the survival of CLL cells, we employed 
SKI-II, which is an orally bioavailable inhibitor for SK1
and SK2 that blocks S1P production and cell
proliferation.8 When peripheral blood mononuclear cells
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Figure 1. SK1/S1PL ratios in resting and activated CLL cells. (A) SK1, SK2 and S1PL mRNA levels were evaluated by qRT-PCR in purified B cells from 30 CLL
patients and 10 age-matched healthy donors. Results were normalized to GAPDH human gene and were represented as relative units (2-DCtx103). Statistical
analysis was performed using the Mann–Whitney test. (B) The graph shows the expression of SK1 relative to b-ACTIN in purified B cells from 7 age-matched
healthy donors and 21 CLL patients evaluated by western blot. Statistical analysis was performed using the Mann–Whitney test. (C) The figure shows the
SK1/S1PL ratios evaluated by qRT-PCR as described above. The dashed line segregates CLL patients with high or low SK1/S1PL ratios, a cutoff of 5 was estab-
lished between patients with less or more than -3 standard deviation (SD) with respect to the healthy control group. Statistical analysis was performed using
the Mann–Whitney test. (D) Purified CLL cells were cultured for 24 hours without (control) or with anti-IgM (a-IgM) plus CD40L (n=12), CpG (n=9) or HS5 cell
line (n=4) and the expression of SK1 and S1PL mRNA were evaluated as described above. Bars represent the mean ± SEM of the SK1/S1PL ratio relative to
control cultures. Statistical analysis was performed using Wilcoxon’s signed-rank test. (E) Leukemic cells from peripheral blood mononuclear cells (PBMCs) of
CLL patients were segregated by IgG or IgM expression.7 Total RNA was purified from the IgG+ cells (PF) and IgM+IgG– cells (QF), and the expression of SK1 and
S1PL mRNA was evaluated as described above. The figure shows the SK1/S1PL ratio of each patient. Patients number 1, 2 and 14 in the Online Supplementary
Table S1 correspond to Patients number 39, 40 and 38, respectively, from our previous paper.6 (F) Bone marrow mononuclear cells from 3 CLL patients were
segregated by CD38 expression as previously detailed.6 Total RNA was purified from the CD19+CD38high fraction and from the CD19+CD38low/negative fraction. SK1
and S1PL mRNA were evaluated as described above. The figure shows the SK1/S1PL ratio of each patient. Patients number 3, 13 and 28 in the Online
Supplementary Table S1 correspond to Patients number 35, 36 and 34, respectively, from our previous paper.6 CLL: chronic lymphocytic leukemia; mRNA; mes-
senger ribonucleic acid.
A B















(PBMCs) from CLL patients were cultured with different
doses of SKI-II, we found that SKI-II induced cell death in
a dose-dependent way (Figure 2A and Online
Supplementary Figure S3A). We observed that the percent-
age of cell death induced by 50 mM of SKI-II inversely
correlated with the basal SK1/S1PL ratios of each sample
(Online Supplementary Figure S3B). In line with this, CLL
patients with low SK1/S1PL ratios were more sensitive
to 50 mM of SKI-II compared to patients with high
SK1/S1PL ratios (Figure 2B). In addition, we found that
non-apoptotic doses of SKI-II (15 mM) increased the sus-
ceptibility of CLL cells to die by other therapeutic agents,
such as fludarabine, bendamustine and ibrutinib (Figure
2C), more markedly in CLL patients with low SK1/S1PL
ratios compared to CLL patients with high SK1/S1PL
ratios (Online Supplementary Figure S3C). Similar results
were recently reported by others showing that SKs inhi-
bition induces apoptosis in primary multiple myeloma,9
acute myeloid leukemia10 and natural killer-large granular
lymphocyte leukemia cells11 and also sensitizes CLL cells
to other therapeutic agents such as EGCG (-epigallocate-
chin-O-3-gallate)12 or lysosome-targeting drugs.13 SKI-II-
induced cell death was associated with a downregulation
of BCL-2 expression in CLL cells (Online Supplementary
Figure S3D), as previously reported in SKI-II-treated gas-
tric cancer cells.14 Thus, CLL samples with low SK1/S1PL
ratios, which were more sensitive to 50 mM of SKI-II
(Figure 2B), showed a higher BCL-2 downregulation
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Figure 2. SKI-II regulates the survival, activation and proliferation of CLL cells. (A) PBMCs from CLL patients (>85% leukemic B cells) were cultured with DMSO
(vehicle) or different doses of SKI-II. The cell death of CD19+ cells was evaluated daily by flow cytometric alterations of light scattering properties and confirmed
by Annexin V (see the Online Supplementary Figure S3A). The figure shows the mean ± SEM of the percentage of CD19+cell death in control and SKI-II cultures
(n=15). Statistical analysis was performed using the Friedman test followed by Dunn's post test. (B) The figure shows the percentage of CD19+ cell death induced
by SKI-II (50 mM) for 72 hours relative to control in CLL patients segregated by low or high SK1/S1PL ratios. Statistical analysis was performed using the Mann–
Whitney test. (C) PBMCs from CLL patients (>85% leukemic B cells) were pre-treated with DMSO (Vehicle) or SKI-II (15 mM) for 30 minutes, and then non-apop-
totic doses of bendamustine (Benda), ibrutinib (Ibru) or fludarabine (Fluda) were added to the cultures. The percentage of CD19+cell death in the cultures was
evaluated daily as mentioned above. Statistical analysis was performed using the Friedman test followed by Dunn's post test. (D) PBMCs from CLL patients
(>85% leukemic B cells) were cultured with DMSO (vehicle) or SKI-II for 24 hours and BCL-2 expression was evaluated by western blot as detailed in Online
Supplementary Materials and Methods. The graph shows the quantitative densitometry protein expression of BCL-2 relative to b-ACTIN (arbitrary units relative
to DMSO) from CLL patients (n=6) with high or low SK1/S1PL ratios in each condition. Statistical analysis was performed using Wilcoxon’s signed-rank test
(*P<0.05). (E) PBMCs from CLL patients were pre-treated with DMSO (Vehicle) or SKI-II (15 mM) for 30 minutes and then cultured with a-IgM plus CD40L. The
expression of the activation marker CD69 on CD19+ cells was evaluated by flow cytometry at 24 hours. The figure shows the percentage of CD69+CD19+ cells
in each condition. Statistical analysis was performed using the Friedman test followed by Dunn's post test. (F) CFSE-labeled PBMC from CLL patients were pre-
treated with DMSO or SKI-II (15 mM) for 30 minutes and then cultured without (control) or with α-IgM plus CD40L. After 5 days of culture, the proliferation of
CLL cells was analyzed using the CFSE dilution assay. The figure shows the percentage of CFSElowCD19+ fraction relative to control culture. Statistical analysis
was performed using Wilcoxon’s signed-rank test (*P<0.01) and the Friedman test followed by Dunn's post test. (G) PBMCs from CLL patients (>85% leukemic
B cells) were cultured with DMSO (vehicle) or SKI-II (50 mM) for 30 minutes and then with or without of S1P 0.5 mM as detailed in Online Supplementary
Materials and Methods. After 48 hours of culture, cell death was evaluated as mentioned above. Bars represent the mean ± SEM of cell death for each treat-
ment relative to control at 48 hours (n=10). Statistical analysis was performed using Wilcoxon’s signed-rank test. (H) CFSE-labeled PBMC from CLL patients
were pre-treated with DMSO or SKI-II (15 mM) for 30 minutes, and then without (control) or with a-IgM plus CD40L in the presence of S1P as detailed in Online
Supplementary Materials and Methods. After 5 days of culture, the proliferation of CLL cells was analyzed using the CFSE dilution assay. The figure shows the
percentage of CFSElowCD19+ fraction relative to control culture. Statistical analysis was performed using Wilcoxon’s signed-rank test. DMSO: dimethyl sulfoxide;




upon SKI-II treatment compared to CLL patients with
high SK1/S1PL ratios (Figure 2D and Online
Supplementary Figure S3E). 
On the other hand, we found that non-apoptotic doses
of SKI-II were able to impair CLL activation induced by
anti-IgM + CD40L at 24 hours, measured by both the
upregulation of CD69 (Figure 2E) and CLL proliferation
evaluated at 5 days (Figure 2F). Remarkably, those sam-
ples with high SK1/S1PL ratios presented a greater
leukemic cell proliferation induced by anti-IgM + CD40L
compared to patients with low SK1/S1PL (Figure 2F),
suggesting that the SK1/S1P/S1PL pathway might regu-
late this proliferative response in CLL. Representative car-
boxyfluorescein succinimidyl ester (CFSE) histograms are
depicted in the Online Supplementary Figure S3F. 
Finally, in order to determine whether S1PRs signaling
may counteract the effects of SKI-II, we added exogenous
S1P to the cultures and found that it rescued CLL cells
from the cell death induced by 50 mM of SKI-II (Figure
2G) and from the anti-proliferative effect of 15 mM of
SKI-II (Figure 2H). These findings suggest that S1P pro-
duction by CLL cells may favor leukemic cell survival and
proliferation in an “inside-out” signaling manner acting
through S1PRs.1
Taken together, the results presented herein and our
previous data showing that the activation of CLL cells
transiently impair the expression of S1PR1,6 allow us to
hypothesize about the role of the SK1/S1P/S1PL axis in
CLL. Thus, the possibility exists that microenvironment
signals from lymphoid tissues, by increasing SK1/S1PL
ratios in leukemic CLL cells, favors S1P production.
Exported S1P can then bind S1PRs, reduce S1PR1 expres-
sion6 and transduce stimulating signals to the leukemic
clone.
In conclusion, our results suggest that the SK/S1P/S1PL
pathway supports the survival and proliferation of CLL
cells, hence favoring the progression of the disease, thus
we encourage the use of SKs inhibitors in combined ther-
apy as a promising treatment option in the future.
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